Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

44. Salvetti A, Abdel-Hag B, Magagna A, et al: Indomethacin
reduces the antihypertensive effect of
enalapril. Clin Exp Hypertens 9:559, 1987.
45. Wilson SL, Poulter NR. The effect of non-steroidal
anti-inflammatory drugs and other commonly
used non-narcotic analgesics on blood pressure
level in adults. J Hypertens 24:1457, 2006.
46. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler
SA: Effect of aspirin on blood pressure in hypertensive
patients taking enalapril or losartan. Am J
Hypertens 12:784, 1999.
47. Nawarskas JJ, Spinler SA: Does aspirin interfere
with the therapeutic efficacy of angiotensin-converting
enzyme inhibitors in hypertension or congestive
heart failure. Pharmacotherapy 18:1041,
1998.
48. Guazzi MD, Campodonico J, Celeste F, et al: Antihypertensive
efficacy of angiotensin-converting
enzyme inhibition and aspirin counteraction. Clin
Pharmacol Ther 63:79, 1998.
49. Balt JC, Mathy MJ, Pfaffendorf M, van Zwieten PA:
Inhibition of angiotensin II-induced facilitation of
sympathetic neurotransmission in the pithed rat: A
comparison between losartan, irbesartan, telmisartan,
and captopril. J Hypertens 19:465, 2001.
50. Lang CC, Stein M, He HB, et al: Angiotensin-converting
enzyme inhibition and sympathetic activity
in healthy subjects. Clin Pharmacol Ther 59:668,
1996.
51. Ranadive SA, Chen AX, Serajuddin AT: Relative
lipophilicities and structural-pharmacological
considerations of various angiotensin-converting
enzyme (ACE) inhibitors. Pharm Res 9:1480, 1992.
52. Gohlke P, Weiss S, Jansen A, et al: AT1 receptor
antagonist telmisartan administered peripherally
inhibits central responses to angiotensin II in conscious
rats. J Pharmacol Exp Ther 298:62, 2001.
53. Culman J, von Heyer C, Piepenburg B, et al: Effects
of systemic treatment with irbesartan and losartan
on central responses to angiotensin II in conscious,
normotensive rats. Eur J Pharmacol 367:255, 1999.
54. Krum H: Differentiation in the angiotensin II receptor
1 blocker class on autonomic function. Curr
Hypertens Rep 3 (Suppl 1):S17, 2001.
55. Fagard R, Amery A, Reybrouck T, et al: Acute
and chronic systemic and hemodynamic effects
of angiotensin-converting enzyme inhibition with
captopril in hypertensive patients. Am J Cardiol
46:295, 1980.
56. Yee KM, Struthers AD: Endogenous angiotensin
II and baroreceptor dysfunction: A comparative
study of losartan and enalapril in man. Br J Clin
Pharmacol 46:583, 1998.
57. Vanhoutte PM: Endothelial dysfunction and inhi-
References to Chapter 9 9-3
bition of converting enzyme. Eur Heart J 19 (Supple
J):J7, 1998.
58. Schiffrin EL, Park JB, Pu Q: Effect of crossing over
hypertensive patients from a beta-blocker to an angiotensin
receptor antagonist on resistance artery
structure and on endothelial function. J Hypertens
20:71, 2002.
59. Schiffrin EL: Effects of antihypertensive drugs on
vascular remodeling: Do they predict outcome in
response to antihypertensive therapy. Curr Opin
Nephrol Hypertens 10:617, 2001.
60. Oparil S, Guthrie R, Lewin AJ, et al: An electivetitration
study of the comparative effectiveness of
two angiotensin II-receptor blockers, irbesartan
and losartan. Irbesartan/Losartan Study Investigators.
Clin Ther 20:398, 1998.
61. Souza Dos Santos RA, Passaglio KT, Pesquero JB, et
al: Interactions between angiotensin-(1–7), kinins,
and angiotensin II in kidney and blood vessels. Hypertension
38:660, 2001.
62. Chappell MC, Allred AJ, Ferrario CM: Pathways
of angiotensin-(1–7) metabolism in the kidney.
Nephrol Dial Transplant 16(Suppl 1):22, 2001.
63. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7):
pharmacological properties and
pharmacotherapeutic perspectives. Eur J Pharmacol
585:303, 2008.
64. White CM: Pharmacologic, pharmacokinetic, and
therapeutic differences among ACE inhibitors.
Pharmacotherapy 18:588, 1998.
65. Cody R: Optimizing ACE inhibitor therapy of congestive
heart failure: Insights from pharmacodynamic
studies. Clin Pharmacokinet 24:59, 1993.
66. Dickstein K: Pharmacokinetics of enalapril in congestive
heart failure. Drugs 32(Suppl 5):40, 1986.
67. Herman AG: Differences in structure of angiotensin-converting
enzyme inhibitors might predict
differences in action. Am J Cardiol 70:102C, 1992.
68. Salvetti A: Newer ACE inhibitors: A look at the future.
Drugs 40:800, 1990.
69. Zusman RM: Effects of converting-enzyme inhibitors
on the renin-angiotensin-aldosterone, bradykinin,
and arachidonic acid-prostaglandin systems:
Correlation of chemical structure and biological
activity. Am J Kidney Dis 10(Suppl 1):13, 1987.
70. Chalmers D, Whitehead A, Lawson DH: Postmarketing
surveillance of captopril for hypertension.
Br J Clin Pharmacol 34:215, 1992.
71. Punzi HD: Safety update: Focus on cough. Am J
Cardiol 72:45H, 1993.
72. Sharif MN, Evans BL, Pylypchuk GB: Cough induced
by quinapril with resolution after changing
to fosinopril. Ann Pharmacother 28:720, 1994.
73. Zusman RM: Angiotensin-converting enzyme in-